Attached files
| file | filename |
|---|---|
| EX-10.1 - EX-10.1 - AMICUS THERAPEUTICS, INC. | a16-15792_1ex10d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): July 29, 2016
AMICUS THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of
Incorporation)
|
001-33497 |
|
71-0869350 |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
1 Cedar Brook Drive, Cranbury, NJ |
|
08512 |
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (609) 662-2000
(Former Name or Former Address, if Changed Since Last Report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 29, 2016, the board of directors (the “Board”) of Amicus Therapeutics, Inc. (the “Company”) amended the Amended and Restated Amicus Therapeutics, Inc. 2007 Equity Incentive Plan (the “Plan”) to provide that participants in the Plan may elect to have shares of common stock of the Company underlying an award withheld to satisfy tax obligations resulting from the vesting, delivery or exercise of such award up to the maximum individual statutory rate attributable to such award (the “Amendment No. 1”). The Board ratified and confirmed the Plan in all other respects. A copy of the Amendment No. 1 is attached hereto as Exhibit 10.1.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits: The Exhibit Index annexed hereto is incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Amicus Therapeutics, Inc. | |
|
|
| |
|
|
|
|
|
Date: July 29, 2016 |
By: |
/s/ Ellen S. Rosenberg |
|
|
|
Ellen S. Rosenberg |
|
|
|
General Counsel and Corporate Secretary |